Brian Skorney
Stock Analyst at Baird
(3.44)
# 965
Out of 4,732 analysts
104
Total ratings
40.54%
Success rate
7.44%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Initiates: Outperform | $46 | $14.13 | +225.55% | 1 | Dec 13, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $10.30 | +191.26% | 1 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Reiterates: Outperform | $72 | $46.88 | +53.58% | 2 | Dec 2, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $14 → $5 | $0.65 | +665.70% | 4 | Nov 29, 2024 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $26 → $20 | $5.25 | +280.95% | 6 | Nov 26, 2024 | |
| BIIB Biogen | Maintains: Outperform | $294 → $300 | $140.55 | +113.45% | 16 | Nov 15, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $44 → $50 | $46.95 | +6.50% | 4 | Nov 13, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $200 → $193 | $118.00 | +63.56% | 9 | Nov 7, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $80 → $95 | $91.84 | +3.44% | 2 | Nov 7, 2024 | |
| ALMS Alumis | Initiates: Outperform | $25 | $7.66 | +226.37% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $4.64 | +115.52% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $272.11 | -20.99% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $58 → $60 | $37.59 | +59.62% | 2 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $143.26 | +25.65% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $5.07 | +452.27% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $37.35 | +66.00% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $2 | $0.54 | +270.44% | 4 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $7.37 | +429.17% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $38.52 | +63.55% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $800 → $760 | $681.58 | +11.51% | 12 | Jun 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $422.00 | -22.99% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $23.86 | -58.09% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $2.92 | +9,146.58% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $5.07 | +18.34% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $3.29 | +9,018.54% | 3 | May 7, 2018 |
Dyne Therapeutics
Dec 13, 2024
Initiates: Outperform
Price Target: $46
Current: $14.13
Upside: +225.55%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $10.30
Upside: +191.26%
Soleno Therapeutics
Dec 2, 2024
Reiterates: Outperform
Price Target: $72
Current: $46.88
Upside: +53.58%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.65
Upside: +665.70%
Enanta Pharmaceuticals
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $5.25
Upside: +280.95%
Biogen
Nov 15, 2024
Maintains: Outperform
Price Target: $294 → $300
Current: $140.55
Upside: +113.45%
Mirum Pharmaceuticals
Nov 13, 2024
Maintains: Outperform
Price Target: $44 → $50
Current: $46.95
Upside: +6.50%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $200 → $193
Current: $118.00
Upside: +63.56%
Gilead Sciences
Nov 7, 2024
Maintains: Neutral
Price Target: $80 → $95
Current: $91.84
Upside: +3.44%
Alumis
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $7.66
Upside: +226.37%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $4.64
Upside: +115.52%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $272.11
Upside: -20.99%
Sep 23, 2024
Maintains: Outperform
Price Target: $58 → $60
Current: $37.59
Upside: +59.62%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $143.26
Upside: +25.65%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $5.07
Upside: +452.27%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $37.35
Upside: +66.00%
Apr 16, 2024
Downgrades: Neutral
Price Target: $20 → $2
Current: $0.54
Upside: +270.44%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $7.37
Upside: +429.17%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $38.52
Upside: +63.55%
Jun 28, 2023
Maintains: Neutral
Price Target: $800 → $760
Current: $681.58
Upside: +11.51%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $422.00
Upside: -22.99%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $23.86
Upside: -58.09%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $2.92
Upside: +9,146.58%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $5.07
Upside: +18.34%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $3.29
Upside: +9,018.54%